Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT06921785 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06921785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06921785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
May 6, 2025
Completion date
March 15, 2030
Enrollment
1,220 (estimated)
Sites
226

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma